RICHMOND HIL, Feb. 28, 2024 /CNW/ – Olympus Canada Inc. (OCI) today announced the expansion of its respiratory care portfolio with the availability of the Spiration™ valve system for the treatment of severe emphysema.
The suction valve system (SVS), previously only indicated for the treatment of prolonged air leaks, is now indicated for the treatment of severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
The Spiration™ Valve System, previously indicated for the treatment of prolonged air leaks, is now available in Canada for the treatment of severe emphysema. (PRNewsfoto/Olympus Canada)
“Olympus Canada is pleased to strengthen its leadership in the respiratory space by increasing the use of the aspiration valve system to treat severe emphysema,” said Mike Lauzon, vice president of the OIC Medical Affairs Unit. “Studies examining the durability of SVS treatment demonstrate the long-term beneficial effects it can have on patients with emphysema. We are pleased to be able to offer a treatment option that could significantly improve people's lives. »
Emphysema is characterized by a loss of elasticity and enlargement of the alveoli in the lungs. Diseased lung lobes become overinflated, causing patients to have difficulty breathing.
The suction valve is an umbrella-shaped device that is placed in the most diseased areas of the lungs during a short bronchoscopic procedure. Treatment with endobronchial valves such as the pull valve, the only endobronchial valve treatment option available in Canada, can improve lung function by redirecting air from overinflated parts of the lungs to healthier parts. Results from the EMPROVE trial demonstrated sustained clinical benefits at 24 months in patients with severe emphysema treated with the aspiration valve system. These benefits include statistically significant improvements in lung function, shortness of breath and quality of life1.
Annual hospitalizations for COPD in Canada have increased significantly since 2002, according to the results of a study published in the Canadian Medical Association Journal. Researchers identified 1.13 million hospitalizations due to COPD. COPD between 2002 and 2017. Annual hospitalizations during this period increased by more than 68%, from 52,937 to 89,384. The study also found that about 21% of admissions were of adults ages 40 to 64. Researchers have suggested that environmental factors such as air pollution and wildfire smoke may be among the factors contributing to the increase in admissions.2
Although smoking rates appear to be plateauing in Canada, researchers predict that the burden of COPD treatment and hospitalizations will increase due to population growth and aging; Smoking is a major contributor to emphysema. According to the study, hospitalizations due to COPD could be avoided through appropriate preventive or early therapeutic interventions.2
Possible side effects that may be associated with the use of the aspiration valve system may include pneumothorax, worsening of COPD symptoms, pneumonia, and shortness of breath. A complete list of prescribing information as well as additional information regarding indications, contraindications, warnings, precautions, and possible complications can be found here.
For more information, please visit the Spiration Valve System product page or the OCI Pulmonology product page for more information on the entire Olympus product line.
About Olympus Canada
Olympus attaches great importance to developing customer-centric solutions. For more than 100 years, Olympus' mission has been to make people's lives healthier, safer and more fulfilling by helping them detect, prevent and treat disease. Olympus Canada Inc. (OCI), a subsidiary of Olympus Corporation of the Americas, manages the company's operations and personnel across Canada in areas such as sales, marketing, services and functional support. Headquartered in Richmond Hill, Ontario, OCI is dedicated to developing our people and supporting local communities. To learn more, visit olympuscanada.com.
1 Criner GJ, Mallea JM, Abu-Hijleh M et al. Sustained clinical benefits of the suction valve system in patients with severe emphysema: 24-month follow-up of EMPROVE [publié en ligne avant l’imprimé, le 10 novembre 2023] Ann Am Thorac Soc. 2023;10.1513/AnnalsATS.202306-520OC
2 Amegadzie, JE et al. “Trends in hospitalizations for chronic obstructive pulmonary disease over 16 years in Canada”. Bar. September 11, 2023, Journal of the Canadian Medical Association. doi.org/10.1503/cmaj.221051
Photo – https://mma.prnewswire.com/media/2350369/SVS_Olympus_Canada.jpg
SOURCE Olympus Canada
Information: CONTACT PERSON: Jennifer Bannan, [email protected]484-896-6170